Filing Flows › Industrials › Accendra Health (ACH)
Accendra Health (ACH) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Accendra Health (ACH) Q3 2026 earnings results →
Q3 2026 Revenue down 14% year over year to $602M · 3¢ of every $1 of revenue lost · operating margin 0.2%
Accendra Health made $602M in Q3 2026 (-14% Y/Y): Diabetes $196M, Sleep therapy $144M, Home respiratory therapy $88.9M. Operating margin 0.2%, net loss $19.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $601.8M in Q3 2026, down 14% year over year and down 2% from the previous quarter. Diabetes was the largest line at 33% of revenue. Sleep therapy lost $41.3M year over year (down 22%), 43% of the total change.
Operating profit was $1.3M, a 0.2% margin (down 3.6 points year over year). Total costs fell 10% while revenue fell 14%. The quarter ended with a net loss of $19.7M, narrower than the previous quarter's $89.1M loss. Net interest and other expense of $39.9M was the main reason.
Operating cash flow was −$17.4M. Non-cash charges added back $38.9M of depreciation and amortization and $2.1M of share-based compensation. Working capital and other items used $38.7M. Capital expenditures of $39.2M exceeded it, leaving free cash flow of −$56.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $602M | -14% | 0.2% | −$19.7M | −$17.4M |
| Q2 2026 | 10-Q | Aug 10, 2026 | $613M | -10% | -5.7% | −$89.1M | −$26.0M |
| Q1 2026 | 10-Q | May 11, 2026 | $628M | -7% | 2.7% | −$6.5M | −$50.1M |
| Q4 2025 | 10-K | Feb 20, 2026 | $709M | +2% | 2.9% | −$56.3M | — |
| Q3 2025 | 10-Q | Oct 31, 2025 | $697M | +2% | 3.8% | −$150M | −$173M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $682M | +3% | -5.8% | −$869M | $37.6M |
| Q1 2025 | 10-Q | May 8, 2025 | $2.6B | +0.7% | 0.8% | −$25.0M | −$35.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 12% of its revenue · Stated in 10-K (name in text, share from XBRL) · source
About Accendra Health
Accendra Health, Inc. (f/k/a Owens & Minor, Inc.) and subsidiaries (Accendra Health, we, us, our or the Company) is a leading nationwide provider of products, technology, and services that supports health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex, and acute health conditions. Together, our trusted brands, Apria and Byram Healthcare, bring nearly 90 years of combined experience in promoting health beyond the hospital in communities across the country. We are headquartered in Richmond, Virginia. The description of our business should be read in conjunction with the consolidated financial statements and supplementary data included in this Form 10-K.
In its own words, from its 10-K, filed Feb 20, 2026.
Accendra Health against its Wholesale-Medical, Dental & Hospital Equipment & Supplies peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ACH Accendra Health | Q3 2026 | $602M | -14% | 0.2% |
| HSIC Henry Schein | Q3 2026 | $3.5B | +4% | 5.6% |
Source: Accendra Health 10-Q on SEC EDGAR · CIK 75252 · Wholesale-Medical, Dental & Hospital Equipment & Supplies
Guidance and outlook
13F: who owns ACH and who is buying
More on ACH
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results